KUALA LUMPUR (May 18): Yong Tai Bhd has entered into debt settlement agreements with 19 creditors to pay off RM46 million owed by issuing 92 million new shares at 50 sen per share.
Yong Tai gets backing from new China partners to expedite 100-acre land development at Impression City, Melaka
KUALA LUMPUR (Sept 16): Yong Tai Bhd has received backing from its new partners from China to resume development of its 100-acre land “Impression City” in Melaka, following a delay due to the Covid-19 pandemic.
Yong Tai receives first batch of SZKT's vaccine, paves way to launch phase 3 clinical trial in Malaysia
KUALA LUMPUR (June 10): Property developer Yong Tai Bhd has announced that its subsidiary YTB Healthcare Sdn Bhd (YTBH) today received the first batch of an inactivated Covid-19 vaccine developed by China-based Shenzhen Kangtai Biological Products Co Ltd (SZKT).
KUALA LUMPUR (June 3): Yong Tai Bhd said its healthcare unit is set to undertake the Covid-19 vaccine phase three clinical trial in Malaysia after the National Pharmaceutical Regulatory Agency (NPRA) granted its approval for the clinical trial import licence.
KUALA LUMPUR (April 27): Property developer Yong Tai Bhd said its healthcare subsidiary has obtained approval from the Ministry of Health's Medical Review & Ethics Committee (MREC) for its Phase III clinical trial study of inactivated Covid-19 trial vaccines in Malaysia.
KUALA LUMPUR (Feb 16): Yong Tai Bhd has denied rumours in the social media that its Covid-19 vaccine application has been rejected by the Ministry of Health’s (MoH) National Pharmaceutical Regulatory Agency.
KUALA LUMPUR (Jan 7): Yong Tai Bhd, which last month proposed the development of a China-based company’s Covid-19 vaccine in Malaysia, today signed up with Tiong Nam Logistics Holdings Bhd to provide distribution services for the vaccine.
Yong Tai to collaborate with Chinese company in Covid-19 vaccine development, distribution in Malaysia
KUALA LUMPUR (Dec 5): Property developer Yong Tai Bhd has entered into a heads of agreement (HoA) with China-based Shenzhen Kangtai Biological Products Co Ltd (SZKT) for a proposed collaboration on the development and exclusive commercialisation of the latter's inactivated Covid-19 vaccine in Malaysia.